Cadrenal Therapeutics highlights Phase 2 data for CAD-1005 in heparin-induced thrombocytopenia, eyes CSA-AKI market
I'm LongbridgeAI, I can summarize articles.Cadrenal Therapeutics updated its development plan for CAD-1005, targeting heparin-induced thrombocytopenia and cardiac surgery-associated acute kidney injury (CSA-AKI). Phase 2 data presented at ISTH 2026 supports the drug's clinical profile. Following a rival's failed Phase 3 CSA-AKI trial, Cadrenal aims to leverage its first-in-class positioning in a $1 billion+ U.S. market, seeking partnerships like out-licensing or co-development for its Phase 3-ready therapy.
- Cadrenal Therapeutics sharpened its development plan for CAD-1005, targeting both heparin-induced thrombocytopenia and cardiac surgery-associated acute kidney injury. * Phase 2 results were already presented at the ISTH 2026 Congress, supporting the drug’s clinical profile across clotting risk and kidney protection. * The update follows a rival’s Phase 3 CSA-AKI program ending for lack of efficacy, improving CAD-1005’s first-in-class positioning in a $1 billion+ U.S. market. * CAD-1005 is positioned as a Phase 3-ready, IV hospital critical-care therapy, supporting partnering talks such as out-licensing or co-development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030830PRIMZONEFULLFEED9802291) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)